Skip to main content

Market Overview

Why Biogen Shares Are Falling

Why Biogen Shares Are Falling

Biogen Inc (NASDAQ: BIIB) shares are trading lower by 7% at $298.83 following reports the company's CEO highlighted a slower-than-anticipated launch of Aduhelm.

Biogen announced on June 7 that the U.S. Food and Drug Administration granted accelerated approval for Aduhelm as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Biogen has a 52-week high of $468.55 and a 52-week low of $223.25.


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: why it's movingNews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at